Related Experiment Video

Updated: Mar 30, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer

Benjamin L Maughan1, Emmanuel S Antonarakis2

  • 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB1-1M45, Baltimore, MD, 21287, USA.

Current Treatment Options in Oncology
|November 6, 2015
PubMed
Abstract

Insights

Androgen receptor splice variants like AR-V7 are key to understanding resistance in metastatic castration-resistant prostate cancer (mCRPC). Detecting AR-V7 may guide treatment selection for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) remains lethal despite numerous treatments.
  • Tumor evolution and acquired resistance mechanisms pose significant challenges in mCRPC management.
  • Androgen receptor (AR) splice variants represent a critical escape mechanism in mCRPC.

Purpose of the Study:

  • To highlight the clinical significance of AR splice variants, particularly AR-V7, in mCRPC.
  • To explore the association between AR-V7 status and treatment response.
  • To discuss AR-V7 as a potential therapeutic target.

Main Methods:

  • Review of current clinical data and emerging evidence on AR splice variants in mCRPC.
  • Analysis of AR-V7 as a prognostic and predictive biomarker.
  • Examination of ongoing therapeutic strategies targeting AR splice variants.

Main Results:

  • AR-V7 is the most clinically relevant AR splice variant and a negative prognostic marker in mCRPC.
  • AR-V7 detection may predict resistance to novel hormonal therapies (abiraterone, enzalutamide) but sensitivity to taxanes (docetaxel, cabazitaxel).
  • AR-V7 status is dynamic and can change under therapeutic pressure.

Conclusions:

  • Understanding AR splice variants like AR-V7 is crucial for optimizing mCRPC treatment selection.
  • AR-V7 serves as a biomarker for predicting treatment response and guiding therapy.
  • Targeting AR splice variants represents a promising future direction for mCRPC therapy.
Keywords:
AR-V7AbirateroneAndrogen receptor variantsCastration-resistant prostate cancerEnzalutamideHormonal therapyResistanceTaxane

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.4K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
26.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68